SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Simonian Nancy A

(Last)

(First)

(Middle)

C/O SYROS PHARMACEUTICALS, INC.

620 MEMORIAL DRIVE, SUITE 300

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2016

3. Issuer Name and Ticker or Trading Symbol
Syros Pharmaceuticals, Inc. [ SYRS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	304,036	D
Common Stock	80,000	I	By the Douglas and Nancy Cole Family Trust f/b/o Bennett H. Cole
Common Stock	80,000	I	By the Douglas and Nancy Cole Family Trust f/b/o William H. Cole

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	05/22/2023	Common Stock	23,454	$1.01	D
Employee Stock Option (right to buy)	⁽²⁾	05/22/2023	Common Stock	75,050	$1.01	D
Employee Stock Option (right to buy)	⁽³⁾	10/22/2024	Common Stock	12,083	$3.04	D
Employee Stock Option (right to buy)	⁽⁴⁾	02/05/2025	Common Stock	71,094	$3.04	D
Employee Stock Option (right to buy)	⁽⁵⁾	06/09/2025	Common Stock	43,048	$3.04	D
Employee Stock Option (right to buy)	⁽⁶⁾	06/09/2025	Common Stock	43,047	$3.04	D
Employee Stock Option (right to buy)	⁽⁷⁾	03/31/2026	Common Stock	93,333	$8.51	D
Series A-2 Preferred Stock	⁽⁸⁾	⁽⁸⁾	Common Stock	66,666	⁽⁸⁾	D

Explanation of Responses:

1. Option vested as to 25% of the shares on July 2, 2013 with the remaining shares vesting in equal monthly installments thereafter through July 2, 2016.

2. Option vests upon the achievement of performance-based criteria, and in any event will vest in full on July 2, 2018.

3. Option vested as to 25% of the shares on September 29, 2015 with the remaining shares vesting in equal monthly installments thereafter through September 29, 2018.

4. Option vested as to 25% of the shares on February 5, 2016 with the remaining shares vesting in equal monthly installments thereafter through February 5, 2019.

5. Option vests as to 25% of the shares on June 9, 2016 with the remaining shares vesting in equal monthly installments thereafter through June 9, 2019.

6. Option vests upon the achievement of performance-based criteria, and in any event will vest in full on June 9, 2021.

7. Option vests as to 25% of the shares on March 31, 2017 with the remaining shares vesting in equal monthly installments thereafter through March 31, 2020.

8. The Series A-2 Preferred Stock is convertible into Common Stock on a 3.75for-one basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney

	/s/ Jorge Conde, attorney-in-fact	06/29/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.